DennisESlaterMD

Clinical Trials

• Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01

  Completed

  Phase 3

• Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Start of enrollment: 2007 May 08

  Active, not recruiting

  Phase 3

• Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer Start of enrollment: 2008 Feb 01

  Active, not recruiting

  Phase 3

• Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10

  Active, not recruiting

  Phase 3

• Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis Start of enrollment: 2009 Nov 01

  Completed

  Phase 3

• Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23

  Active, not recruiting

  Phase 3

• Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15

  Completed

  Phase 3

• Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2009 Nov 01

  Active, not recruiting

  Phase 3

• Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Start of enrollment: 2009 Nov 17

  Active, not recruiting

  Phase 3

• Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24

  Active, not recruiting

  Phase 3

• Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14

  Completed

  Phase 3

• Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery Start of enrollment: 2011 Jan 01

  Active, not recruiting

  Phase 2

• Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16

  Completed

  Not Applicable

• Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06

  Active, not recruiting

  Phase 3

• S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08

  Active, not recruiting

  Phase 3

• BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29

  Completed

  Phase 2

• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Dec 13

  Active, not recruiting

  Phase 3

• Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

  No longer available

• A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09

  Completed

  Phase 3

• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01

  Completed

  Phase 2

• Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01

  Completed

  Phase 2, Phase 3

• Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29

  Active, not recruiting

  Phase 3

• Join now to see all